Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANCHOR: ABBV-CLS-628 in ADPKD
NCT06902558Phase 2Recruiting
- Sponsor
- Calico Life Sciences
- Start
- Jun 2025
- Primary completion
- Aug 2029
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of ABBV-CLS-628 in autosomal dominant polycystic kidney disease (ADPKD) (4 arms), sponsored by Calico Life Sciences. Primary endpoints: Cumulative Rate of Change from Baseline in Total Kidney Volume at 96 weeks and Number of Participants with Adverse Events at 118 weeks. Started Jun 2025; status: recruiting.
02
Drugs
ABBV-CLS-628
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT06902558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902558.